Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-67.85%
operating margin TTM
-80.76%
revenue TTM
659.18 Thousand
revenue per share TTM
0.01$
valuation ratios | |
|---|---|
| pe ratio | -10.34 |
| peg ratio | -0.32 |
| price to book ratio | 2.51 |
| price to sales ratio | 6.96 |
| enterprise value multiple | -12.25 |
| price fair value | 2.51 |
profitability ratios | |
|---|---|
| gross profit margin | 89.12% |
| operating profit margin | -80.76% |
| pretax profit margin | -69.1% |
| net profit margin | -67.85% |
| return on assets | -21.13% |
| return on equity | -23.43% |
| return on capital employed | -28.56% |
liquidity ratios | |
|---|---|
| current ratio | 8.02 |
| quick ratio | 7.91 |
| cash ratio | 3.26 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 134.17 |
| operating cycle | 195.86 |
| days of payables outstanding | 79.17 |
| cash conversion cycle | 116.68 |
| receivables turnover | 5.92 |
| payables turnover | 4.61 |
| inventory turnover | 2.72 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -37.15 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.04 |
| cash per share | 4.27 |
| operating cash flow per share | -1.00 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -37.15 |
| short term coverage ratios | -596.30 |
| capital expenditure coverage ratio | -27.16 |
Frequently Asked Questions
When was the last time Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) reported earnings?
Day One Biopharmaceuticals, Inc. (DAWN) published its most recent earnings results on 04-11-2025.
What is Day One Biopharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)'s trailing twelve months ROE is -23.43%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Day One Biopharmaceuticals, Inc. (DAWN) currently has a ROA of -21.13%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did DAWN's net profit margin stand at?
DAWN reported a profit margin of -67.85% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is DAWN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 8.02 in the most recent quarter. The quick ratio stood at 7.91, with a Debt/Eq ratio of 0.01.